Allergan Comes To Q3 Call With Deal News, But Nothing On Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan announced a licensing deal with Mimetogen to commercialize a TrkA agonist for the treatment of dry eye disease, coinciding with its third quarter earnings call and R&D day, but avoided discussion of the elephant in the room.